Oragenics, Inc. Wins $0.5 Million Phase II SBIR Grant for Its Unique Antibiotic Technology
19 Février 2008 - 3:00PM
Marketwired
ALACHUA, FL , a biotechnology development company focused on
infectious diseases, announced today that it has been selected to
receive a $0.5 million grant to advance development of its unique
small peptide antibiotic synthesis program using the company's
proprietary Differentially Protected Orthogonal Lanthionine
Technology (DPOLT(TM)). This two-year Phase II grant, awarded
through the Small Business Innovation Research (SBIR) program of
the National Science Foundation (NSF), will support studies focused
on the synthesis and testing of our lead antibiotic,
MU1140(TM).
"Oragenics is very pleased with our success in obtaining this
funding," said Dr. Jeffrey Hillman, Chief Scientific Officer and
principal investigator for this project. "The recent publicity
about hospital-acquired infections and MRSA (methicillin resistant
Staphylococcus aureus) has emphasized the tremendous need for new
and novel antibiotics to replace the ones that are failing."
Successful development of DPOLT(TM) will enable, for the first
time, large-scale commercial production of MU1140(TM) and other
related antibiotics, which the Company believes will be effective
in treating some of the most troublesome human infections. On a
related matter, a paper describing the novel mechanism by which
MU1140(TM) kills bacteria was recently published in the prestigious
international scientific journal "Biochemistry." The "on-line" text
of the article was published on February 12, 2008.
About Oragenics
Oragenics, Inc. is a biopharmaceutical company with a pipeline
of proprietary technologies. The Company has a number of products
in discovery, preclinical and clinical development, with a
concentration in the main therapeutic area of infectious diseases.
Our core pipeline includes products and supporting platform
technologies for use in the treatment and diagnosis of bacterial
infections.
Safe Harbor Statement: Under the Private Securities Litigation
Reform Act of 1995: This release includes forward-looking
statements that reflect Oragenics' current views with respect to
future events and financial performance. These forward-looking
statements are based on management's beliefs and assumptions and
information currently available. The words "believe," "expect,"
"anticipate," "intend," "estimate," "project" and similar
expressions that do not relate solely to historical matters
identify forward-looking statements. Investors should be cautious
in relying on forward-looking statements because they are subject
to a variety of risks, uncertainties, and other factors that could
cause actual results to differ materially from those expressed in
any such forward-looking statements. These factors include, but are
not limited to those set forth in our most recently filed annual
report on Form 10-KSB and quarterly report on Form 10-QSB, and
other factors detailed from time to time in filings with the
Securities and Exchange Commission. We expressly disclaim any
responsibility to update forward-looking statements.
Contact: Oragenics, Inc. Dotti Delfino 386-418-4018 X232
www.oragenics.com
Oragenics (AMEX:ONI)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Oragenics (AMEX:ONI)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Oragenics, (American Stock Exchange): 0 recent articles
Plus d'articles sur Oragenics